Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients
Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients
Sponsor: National Institute on Minority Health and Health Disparities (NIMHD)
Terminated
Decrease in COVID-19 cases locally
Other terminated trials from National Institute on Minority Health and Health Disparities (NIMHD)
- Anxiety · Phase NA · Jul 2025
- Anxiety · Phase NA · May 2025
- Depression · Phase NA · Nov 2024
- COVID-19 · Phase NA · Jun 2024
- Obesity · Phase NA · Aug 2015
See all terminations from National Institute on Minority Health and Health Disparities (NIMHD)
This PHASE2 trial investigates COVID-19 and is currently terminated or withdrawn. National Institute on Minority Health and Health Disparities (NIMHD) leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Sep 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Minority Health and Health Disparities (NIMHD)
- University of Hawaii
For direct contact, visit the study record on ClinicalTrials.gov .